Close
Nordic 9Nordic 9

Access Biotechnology (investor - Corporate Investor)

United States accessbio-tech.com
See something wrong or missing? Let us know
Offices:New York

Access Biotechnology is an investment arm of Access Industries that focuses on private and public biopharma companies across therapeutic areas, modalities, and development stages – from discovery-stage technology platforms to late-stage clinical programs.

Average round investment:138.98M USD
Average number per year:1.0
Distribution: 2025 (1)2023 (1)
Portfolio companies: United Kingdom Draig TherapeuticsDenmark Hemab
Mostly invests in: United Kingdom United Kingdom (1) Biotech (2)

2 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Access Biotechnology

Name Criteria
United States Ridgeback Capital Management
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Monashee Investment Management
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Czech Republic PPF Group
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Singapore Lyfe Capital
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
China Lilly Asia Ventures
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States BrightEdge Fund
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Wellington Management
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Norway Watrium
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Denmark ATP
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.6
  • Active last 12 months: Yes
United Arab Emirates Chimera Investment
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Top